Current Rheumatology Reports

, Volume 1, Issue 2, pp 135–138

The treatment of rheumatoid arthritis: A review of recent clinical trials

  • Ted Mikuls
  • Larry Moreland
Clinical Trials Review

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Pincus T, Callahan LF, Sale WG, et al.: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984, 27:864–872.PubMedCrossRefGoogle Scholar
  2. 2.
    Mitchell DM, Spitz PW, Young DY, et al.: Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986, 29:706–714.PubMedCrossRefGoogle Scholar
  3. 3.
    Stone CE: The lifetime economic costs of rheumatoid arthritis. J Rheumatol 1984, 11:819–827.PubMedGoogle Scholar
  4. 4.
    Felson DT, Anderson JJ, Meenan RF: Use of short-term efficacy/ toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A meta-analysis of published clinical trials. Arthritis Rheum 1992, 35:1117–1125.PubMedCrossRefGoogle Scholar
  5. 5.
    Pincus T, Marcum SB, Callahan LF: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second-line drugs and prednisone. J Rheumatol 1992, 19:1885–1894.PubMedGoogle Scholar
  6. 6.
    Weinblatt ME, Maier AL, Fraser PA, et al.: Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol 1998, 25:238–242.PubMedGoogle Scholar
  7. 7.
    Pinals RS, Masi AT, Larsen RA and the Subcommittee for the Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981, 24:1308–1315.PubMedCrossRefGoogle Scholar
  8. 8.
    Egsmose C, Lund B, Borg G, et al.: Patients with rheumatoid arthritis benefit from early second-line therapy. Five year follow-up of a prospective double-blind, placebo-controlled trial. J Rheumatol 1995, 22:2208–2213.PubMedGoogle Scholar
  9. 9.
    Van der Heide A, Jacobs JWG, Bijlsma JWJ, et al.: The effective-ness of early treatment with ’second-line’ antirheumatic drugs, a randomised, controlled trial. Ann Intern Med 1996, 124:699–707.PubMedGoogle Scholar
  10. 10.
    Munro R, Hampson R, McEntegart A, et al.: Improved functional outcomes in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998, 57:88–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Maravic M, Bologna C, Daures J, et al.: Radiologic progression in early rheumatoid arthritis treated with methotrexate. J Rheumatol 1999, 26:262–267.PubMedGoogle Scholar
  12. 12.
    Rich E, Moreland LW, Alarcon GS: Paucity of radiographic progression in rheumatoid arthritis treated with metho-trexate as the first disease modifying antirheumatic drug. J Rheumatol 1999, 26:259–261.PubMedGoogle Scholar
  13. 13.
    Fuchs HA, Kaye JJ, Callahan LF, et al.: Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989, 16:585–591.PubMedGoogle Scholar
  14. 14.
    Felson DT, Anderson JJ, Meenan RF: The efficacy and toxicity of combination treatment in rheumatoid arthritis. A meta-analysis. Arthritis Rheum 1994, 37:1487–1491.PubMedCrossRefGoogle Scholar
  15. 15.
    Tugwell P, Pincus T, Yocum D, et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995, 333:137–141.PubMedCrossRefGoogle Scholar
  16. 16.
    O’Dell JR, Haire C, Erikson N, et al.: Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine plus hydroxychloroquine, or a combination of all three medica-tions. N Engl J Med 1996, 334:1287–1291.PubMedCrossRefGoogle Scholar
  17. 17.
    O’Dell JR, Paulsen G, Haire C, et al.: Comination DMARD therapy with methotrexate (M) -sulfasalazine (S) - hydroxy-chloroquine (H) in rheumatoid arthritis (RA): continued efficacy with minimal toxicity at 5 years. Arthritis Rheum 1998, 41(suppl):S596.Google Scholar
  18. 18.
    Boers M, Verhoeven AC, Markusse HM, et al.: Randomised comparison of combined step-down prednisilone, metho-trexate and sulphasalazine with sulphasalazine alone in earl rheumatoid arthritis. Lancet 1997, 350:309–318.PubMedCrossRefGoogle Scholar
  19. 19.
    Mottonen T, Hannonen P, Leirisalo-Repo M, et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999, 353:1568–1573.PubMedCrossRefGoogle Scholar
  20. 20.
    Fox RI: Mechanisms of action of leflunomide. J Rheumatol 1998, 25(suppl 53):20–26.Google Scholar
  21. 21.
    Weaver A, Caldwell J, Olsen N, et al.: Treatment of active rheumatoid arthritis with leflunomide compared to placebo of methotrexate. Arthritis Rheum 1998, 41(suppl):S131.Google Scholar
  22. 22.
    Smolen JS, Kalden JR, Scott DL, et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999, 353:259–266.PubMedCrossRefGoogle Scholar
  23. 23.
    Plosker GL, Wagstaff AJ: Leflunomide. Clin Immunother 1996, 6:300–306.Google Scholar
  24. 24.
    Kalden JR, Williams BD, Kvien TK, et al.: Rapid onset of action of leflunomide, a novel immunomodulatory agent for rheumatoid arthritis. Rheumatol Eur 1998, 27(suppl 2):157.Google Scholar
  25. 25.
    Kremer JM: Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999, 29:14–26.PubMedCrossRefGoogle Scholar
  26. 26.
    Weinblatt ME, Kremer JM, Coblyn JS, et al.: Pharmacokinetics, safety, and efficacy of combination treatment with metho-trexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999, 42:1322–1328.PubMedCrossRefGoogle Scholar
  27. 27.
    Moreland LW, Baumgartner SW, Schiff MH, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337:141–147.PubMedCrossRefGoogle Scholar
  28. 28.
    Moreland LW, Schiff MH, Baumgartner SW, et al.: Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999, 130:478–486.PubMedGoogle Scholar
  29. 29.
    Moreland LW, Baumgartner SW, Tindall E, et al.: Long-term safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc, Enbrel) in DMARD refractory rheumatoid arthritis (RA). Arthritis Rheum 1998, 41(Suppl):S364.CrossRefGoogle Scholar
  30. 30.
    Elliott MJ, Maini RN, Feldmann M, et al.: Treatment of rheu-matoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-a. Arthritis Rheum 1993, 36:1681–1690.PubMedCrossRefGoogle Scholar
  31. 31.
    Elliott MJ, Maini RN, Feldmann M, et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105–1110.PubMedCrossRefGoogle Scholar
  32. 32.
    Elliott MJ, Maini RN, Feldmann M, et al.:Repeated therapy with monoclonal antibody to tumor necrosis factor-a (cA2) in patients with rheumatoid arthritis. Lancet 1994, 344 1125–1127.PubMedCrossRefGoogle Scholar
  33. 33.
    Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552–1563.PubMedCrossRefGoogle Scholar
  34. 34.
    Bresnihan B, Alvaro-Gracia JM, Cobb M, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196–2204.PubMedCrossRefGoogle Scholar
  35. 35.
    Koopman WJ, Moreland LW: Rheumatoid arthritis: anti-cytokine therapies on the horizon. Ann Intern Med 1998, 128:231–233.PubMedGoogle Scholar
  36. 36.
    Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340:253–259.PubMedCrossRefGoogle Scholar
  37. 37.
    Kirwan JR and the Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995, 333:142–146.PubMedCrossRefGoogle Scholar
  38. 38.
    Hickling P, Jacoby RK, Kirwan JR, et al.: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998, 37:930–936.PubMedCrossRefGoogle Scholar
  39. 39.
    Ranges GE, Sriram S, Cooper SM: Prevention of collagen induced arthritis by in vitro treatment with anti-CD4. J Exp Med 1985, 162:1105–1110.PubMedCrossRefGoogle Scholar
  40. 40.
    Trentham DE, Dynesus-Trentham RA, Orav EJ, et al.: Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993, 261:1727–1730.PubMedCrossRefGoogle Scholar
  41. 41.
    Sieper J, Kary S, Sorensen H, et al.: Oral type II collagen treat-ment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996, 39:41–51.PubMedCrossRefGoogle Scholar
  42. 42.
    Barnett ML, Kremer JM, St. Clair EW, et al.: Treatment of rheu-matoid arthritis with oral type II collagen: results of a multi-center, double-blind, placebo-controlled trial. Arthritis Rheum 1998, 41:290–297.PubMedCrossRefGoogle Scholar
  43. 43.
    McKown KM, Carbone LD, Kaplan SB, et al.: Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 1999, 42:1204–1208.PubMedCrossRefGoogle Scholar
  44. 44.
    O’Dell JR, Haire CE, Erikson N, et al.: Treatment of early rheu-matoid arthritis with minocycline or placebo. Arthritis Rheum 1997, 40:842–848.PubMedCrossRefGoogle Scholar
  45. 45.
    O’Dell JR, Paulsen G, Haire CE, et al.: Treatment of early sero-positive rheumatoid arthritis with minocycline. Four-year followup of double-blind, placebo-controlled trial. Arthritis Rheum 1999, 42:1691–1695.PubMedCrossRefGoogle Scholar
  46. 46.
    Felson D, Furst D, LaValley M, et al.: Results of a randomized double blind trial of the Prosorba® column for the treatment of severe rheumatoid arthritis. Arthritis Rheum 1998, 41(Suppl):S1992.Google Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Ted Mikuls
    • 1
  • Larry Moreland
    • 1
  1. 1.Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirmingham

Personalised recommendations